Sciamanna Marta

Dott.ssa Marta Sciamanna

Pubblicazioni scientifiche: PubMed

Linea di ricerca: UOS Retina Medica

Principali specializzazioni: Patologie vitreo-retiniche, Degenerazione maculare legata all'età, Retinopatia Diabetica, Maculopatie

Attività medica: La Dott.ssa Sciamanna dal 2008 svolge attività clinico scientifica nell’Unità Operativa di ricerca “Retina Medica” presso l’IRCCS Fondazione G.B. Bietti dove i occupa di patologie retiniche e diagnostica (OCT, Fluorangiografia). Partecipa a numerosi trials clinici internazionali come Study Coordinator e Co-investigator. I suoi maggiori interessi riguardano le patologie maculari.


Formazione

Luglio 1994 - Laurea in Medicina e Chirurgia presso L’Università Cattolica del Sacro Cuore Policlinico. A. Gemelli, Roma.
Ottobre 1998 - Specializzazione in Oftalmologia presso l’Università degli Studi di Roma “La Sapienza”.

Ruoli

Dal 2008  Ricercatore  linea Retina medica presso Fondazione G.B.Bietti –IRCCS via Livenza 3, 00198 Roma
2010-2016 Attività assistenziale presso il centro per le maculopatie della Fondazione G.B.Bietti-IRCCS presso la ASL complesso ospedaliero S.Giovanni -Addolorata, Via di santo Stefano Rotondo 6, Roma

  • MONTBLANC Study. A 12-month randomized, double-masked, multicenter, phase II study assessing safety and efficacy of verteporfin (Visudyne®) photodynamic therapy administered in conjunction with LucentisTM versus LucentisTM monotherapy in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Co-Investigator.
  • DEGAS Study. A phase II prospective, randomized, multi-center, diabetic macular edema dose ranging, comparator study evaluating the efficacy and safety of PF-04523655 versus laser therapy (DEGAS).
    Study Coordinator.
  • GALILEO Study. A randomized, double-masked, sham-controlled phase 3 study of the efficacy, safety, and tolerability of repeated intravitreal administration of VEGF Trap-Eye in subjects with macular edema secondary to central retinal vein occlusion (CRVO).
    Co-Investigator.
  • Multicentric, phase 3b, randomized, single blind, controlled, 2 years follow up to evaluate the efficacy and safety of 0.5 mg ranibizumab treat and extend vs 0.5 mg ranibizumab as needed in patients with diabetic macular edema (RETAIN).
    Study coordinator.
  • VIVID DME Study. A randomised, double masked, active controlled, phase III study of the efficacy and safety of repeated doses of intravitreal VEGF Trap-Eye in subjects with diabetic macula edema. A Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of 700 μg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) to Ranibizumab in Patients with Diabetic Macular Edema.
    Co-investigator
  • A 12-month, phase IIb, randomized, single-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in Treat and Extend regimen compared to Monthly regimen, in patients with neovascular age-related macular degeneration (TREND)
    Study-coordinator
  • A Phase II multicenter, randomizes, double-maskerd, sham-controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patents with geographic atrophy secondary to o age-related macular degeneration. (CHROMA)
    Study coordinator
  • Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (SEQUOIA)
    Study coordinator
  • An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the         efficacy, safety, and tolerability of 2 mg aflibercept administered by intravitreal injections using two different treatment regimens to subjects with neovascular age-related macular degeneration (nAMD) (AZURE)
    Co-investigator
  • Managing neovascular age-related macular degeneration (nAMD) over 2 years with a Treat and Extend (T&E) regimen of 2 mg intravitreal (IVT) aflibercept - a randomized, open-label, active-controlled, parallel-group phase IV/IIIb study (ARIES)
    Co-investigator
  • A multi-center, single-arm, interventional Phase 4 study to evaluate a Treat and Extend regimen of intravitreal aflibercept for treatment of macular edema secondary to central retinal vein occlusion  (CENTERA)
    Co-investigator
  • Capitolo Testo High Miopia “Optical devices in highly myopic eyes” Scassa C, Sciamanna M, Gazzaniga D. 2004
  • Capitolo Testo High Miopia “ OCT in differential Diagnosis of macular pathologies in high Miopia” Scassa C, Ripandelli G, Sciamanna M. 2004